The PRWIRE Press Releases https:// 2018-11-06T02:25:28Z Mundipharma acquires product to help 1 million Australians with difficulty swallowing medication 2018-11-06T02:25:28Z mundipharma-acquires-product-to-help-1-million-australians-with-difficulty-swallowing-medication Mundipharma is proud to announce it has acquired the exclusive Australian and New Zealand distribution rights to the medication lubricant Gloup™, from Evomed Pty Limited (Evomed). Gloup™ is a medication lubricant that helps patients swallow tablets, capsules and powder medications more easily and is designed to have with minimal impact on medication absorption. More than 1 million Australians experience difficulty swallowingi, including 40-50 per cent of people living in aged care facilitiesii. Difficulty swallowing can develop at any stage of life and those at most risk include people taking multiple medications, anyone consuming large tablets, people with a dry mouth caused by medication or illness,children transitioning to tablets and oncology patients. It can also develop as a result of Parkinson’s disease, motor neuron disease, dementia and damage to the brain or structures of the head and neckiii. Crushing tablets or opening capsules can impact the effectiveness and risks associated with some medicationsiv and the Society of Hospital Pharmacists Australia’s Don’t Rush to Crush Handbook recommends the use of medication lubricantsv for patients with difficulty swallowing. Gloup™ is a slippery gel consisting of food based ingredients that have no known interactions with medications. Gloup™ is designed so that its ingredients break down almost immediately in the acidic environment of the stomach to minimise impact on medication absorption. “Mundipharma is a trusted source of information and education across primary care, hospital, aged care and retail pharmacy, so I am thrilled that Mundipharma will be able to help even more Australians benefit from this important product,” said Jane Orr, Managing Director of Mundipharma Australia and New Zealand. “Gloup™ addresses a serious need for many patients who are acutely unwell and may be in significant pain, making this aspect of their care so much easier and more comfortable.” This deal continues the growth and diversification of Mundipharma’s product portfolio, following this year’s launch of mundicare® Cold Defence, the securing of exclusive Australian and New Zealand distribution rights to PAINmate®, ActiPatch™ and AccuVein® – also from Evomed, as well as the acquisition of Tolmar Australia. This is in addition to the successful PBS listing of a medication for Peripheral T-Cell Lymphoma earlier this year. Mundipharma’s portfolio now includes 37 health care products across pain, oncology, ophthalmology, respiratory, first aid, hydration, the common cold, vein illumination technology and now, medication administration. Gloup™ is available in vanilla, orange, strawberry/banana, and low sugar cherry, and two levels of thickness, depending on the severity of swallowing difficulty. Always read the label. Use only as directed. If symptoms persist, see your healthcare professional Further information is available from Mundipharma Pty Limited, 88 Phillip Street, Sydney, NSW 2000. Phone 1800 188 009 or email medinfo@mundipharma.com.au. ® MUNDICARE is a registered trademark of MUNDIPHARMA. PAINMATE is a registered trademark. GLOUP is a trademark of Paxtree Limited. ACCUVEIN is a trademark of AccuVein Inc. ACTIPATCH is a trademark of BioElectronics Corporation. References i Speech Pathology Australia’s submission to Australian Government’s Department of Health: Electronic Health Records and Healthcare Identifiers: Legislation Discussion Paper. 24 June 2015. https://www.myhealthrecord.gov.au/sites/g/files/net5181/f/094_-_speech_pathology_australia.pdf?v=1526130629 ii https://www.racgp.org.au/download/documents/Guidelines/silverbook.pdf iii Speech Pathology Australia Fact Sheet: Swallowing. https://www.speechpathologyaustralia.org.au/spaweb/Document_Management/Public/Fact_Sheets.aspx#anchor_swal iv Australian Government Department of Health. Guiding principles for medication management in residential aged care facilities. http://www.health.gov.au/internet/main/publishing.nsf/content/guide-med-mgmt-aged-care. v The Society of Hospital Pharmacists Australia, 2015, Australian Don’t Rush to Crush Handbook, 2nd ed., p.21. AU-4857 G MEDICAL PURCHASES TELERHYTHMICS LLC, MEDICAL DIAGNOSTIC MONITORING SERVICE PROVIDER 2018-11-02T02:32:40Z g-medical-purchases-telerhythmics-llc-medical-diagnostic-monitoring-service-provider Expands infrastructure to increase nationwide footprint and services for remote vital signs monitoring healthcare services in the USA Provides additional capacity, access to technologies and payer network November 2, 2018 - Sydney, Australia – Mobile and e-Health company G Medical Innovations Holdings Ltd (G Medical or the Company) (ASX: GMV) is pleased to announce that its wholly owned Delaware incorporated subsidiary, G Medical Innovations USA Inc, has executed an agreement to acquire 100% of the outstanding membership interest of Telerhythmics LLC (Telerhythmics) (a Tennessee limited liability company), a US based cardiac diagnostic monitoring services provider. Telerhythmics, based outside Memphis, Tennessee, is a 24-hour cardiac diagnostic monitoring service used by hospitals and physician offices, and provides its monitoring services throughout the eastern region of the U.S. G Medical will acquire all the outstanding membership interests of Telerhythmics from NASDAQ listed imaging technologies company Digirad Corp (NASDAQ: DRAD) for a total up front consideration of US$1,950,000, subject to working capital adjustments. Completion of the agreement remains subject to the satisfaction of certain customary conditions precedent, including the receipt of any necessary consents from third parties including but not limited to government authorities. Telerhythmics, LLC., booked historical revenue from 1 January 2018 to 30 September 2018 of ~US$3.174M1 . The Telerhythmics acquisition, in addition to the Company’s acquisition of Cardiostaff Diagnostic Services Inc (as announced on 30 October 2017) will create a sizable player in the cardiac diagnostic US monitoring space, and in addition, provide G Medical with a solid base of business across the Southeast and Southwest territories. Telerhythmics is a Medicare and Medicaid designated IDTF (Independent Diagnostic Testing Facility) that provides physician practices and hospitals with arrhythmia monitoring services including mobile cardiac telemetry ("MCT"), cardiac event monitoring, Holter monitoring, and pacemaker analysis. The Telerhythmics acquisition will substantially increase insurance coverage and create a distinct competitive advantage, providing G Medical with ~100 commercial payor agreements across local, regional and national markets and an additional 30-35M covered lives (individuals insured); with the Company’s aggregated sum increasing to ~100M+ covered lives when considering existing G Medical Diagnostic Services payor agreements. Via the acquisition, G Medical will also gain access to several large health systems including Baptist, Ochsner, and HCA, and also to existing agreements in place with large insurance providers such as Blue Cross Blue Shield (BCBS), which has current reimbursement status for MCT (auto detect auto send) monitoring device. Further, Page 2 of 3 the Company’s regulatory approved medical devices will be translated to existing customers of both Telerhythmics and G Medical, providing for a superior technology offering and monitoring services when compared to traditional Holter monitoring. Telerhythmics, LLC., was established in 1996. It has long been recognized for superior clinical patient monitoring given its foundation of employing experienced critical care nurses. Telerhythmics’ business is synergistic and complementary to G Medical’s existing infrastructure and operations following the Company’s successful acquisition and integration of CardioStaff, and further increases the Company’s nationwide footprint and services for remote vital signs monitoring healthcare services across the US. Commenting on the latest acquisition, G Medical CEO Dr. Yacov Geva, said: “Acquiring Telerhythmics further strengthens our Company’s US footprint as we further focus our efforts to become a leader in complete (endto-end) and comprehensive vital signs medical monitoring and cardiac diagnostic services across the US. Telerhythmics brings additional payer contracts, clinical and commercial scalability, access to current monitoring technologies and an existing platform to launch our proprietary medical devices with the aim to further grow our market share in this important area of digital health delivery.” Cardiac diagnostic monitoring and remote vital signs monitoring healthcare services is a rapidly growing industry in the US and the Company is well positioned to become an emerging leader in the E-Health and Vital Signs Monitoring space. The Company continues its preparations towards the submission of its F-1 Registration Statement towards a Dual-Listing on the NASDAQ Stock Exchange, where a number of the Company’s peers are currently listed. About G Medical Products G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals. The ‘Prizma’ Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The ‘Prizma’ allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members. G Medical also offers a professional real-time patient continuous monitoring solution, G Medical’s Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings. - Ends - Contact: Corporate Advisors Otsana Capital 108 Outram Street West Perth WA 6005 Telephone: +61 8 9486 7244 www.otsana.com Investor Relations Viriathus Australia Level 8/525 Flinders Street Melbourne VIC 3000 Telephone: +61 2 8667 5360 www.viriathus.com Media Enquiries Closer Communications David Wolf Tel: + 61 411 111 787 david@closer.com.au About G Medical Innovations G Medical (ASX: GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity. The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories. For more information on G Medical, please visit www.gmedinnovations.com CE, FDA & CFDA Approval Granted for Guangzhou China Production Facility 2018-10-30T05:04:29Z ce-fda-cfda-approval-granted-for-guangzhou-china-production-facility October 30, 2018 – Sydney, Australia – Mobile and e-Health company G Medical Innovations Holdings Ltd (“G Medical” or the “Company”) (ASX: GMV) is pleased to announce it has successfully completed the independent audit process to achieve CE, FDA and CFDA regulatory approval for the Company’s Production Facility in Guangzhou China. The Company is proud to inform its shareholders that it achieved excellent results during the multistage independent audit process conducted during September and October for all three regulatory bodies (CE, FDA and CFDA). The full audit has now been completed, and the results of the audit are expected to be published and searchable to the public later this week via the following directory; https://www.sgsgroup.com.cn/en/certified-clients-and-products/certified-client-directory The Company expects to receive its final certification documentation from the Regulatory bodies within 3 weeks. This is a significant milestone for the Company which intends to utilise the full production capacity of its Guangzhou facility. As previously announced to the market, the Company has numerous agreements in place globally and the approvals granted for the Guangzhou Facility enables the Company to commence production and distribution to those territories which recognise CE, FDA and CFDA certification and have already granted regulatory approval for the Company’s medical devices. G Medical CEO Dr. Yacov Geva said, “We are very pleased to have achieved CE, FDA and CFDA approval, which exemplifies the high-quality of our Production Facility and our strong in-Country relationships. The Company has been committed to achieving this major milestone in record timeframes and we now look forward to being able to meet the demand from our global partnerships and rapidly execute our commercial plans.” G Medical has a strong pipeline of customer demand and the increased production capacity positions the Company to fulfil its expansion into the rapidly growing E-Health market. As the Company continues its preparations for the listing of its Chinese subsidiary, Guangzhou Yimei Innovative Medical Science and Technology Co. Ltd, on the main board of The Hong Kong Stock Exchange (HKSE), the granting of CE, FDA and CFDA approval was an important achievement in this process. The Company requests that its securities stay in trading halt, pending an announcement in respect of a convertible note capital raising and a material acquisition. The Company requests the trading halt until the market opens on 31 October 2018 or until the announcement is made, whichever is the earlier. Corporate Advisors Otsana Capital 108 Outram Street West Perth WA 6005 Telephone: +61 8 9486 7244 www.otsana.com Investor Relations Viriathus Australia Level 8/525 Flinders Street Melbourne VIC 3000 Telephone: +61 2 8667 5360 www.viriathus.com Media Enquiries Closer Communications David Wolf Tel: + 61 411 111 787 david@closer.com.au About G Medical Innovations G Medical (ASX: GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity. The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories. For more information on G Medical, please visit www.gmedinnovations.com Dr Anh speaks out in response to the media frenzy about the issue of plastic surgeons’ social media being responsible for body image anxiety. 2018-10-25T02:16:42Z dr-anh-speaks-out-in-response-to-the-media-frenzy-about-the-issue-of-plastic-surgeons-social-media-being-responsible-for-body-image-anxiety The solution to low body image issues is quite simple, argues Perth Female Plastic Surgeon, Dr Anh. She writes an open letter in response to the media frenzy about the issue of plastic surgeons’ social media being responsible for body image anxiety. It is disappointing to read the gross generalisations in the articles in the Daily telegraph and the Sydney Morning Herald that suggest that Plastic Surgeons are part of the growing problem of body image anxieties. As a female plastic surgeon in Perth who is active on social media, as a woman who has had her fair share of insecurities about her body, as a mum of 3 children including a 12 year old daughter, I would argue that this is a sweeping generalisation and one I find negative and somewhat insulting to those of us who are against body shaming and passionate about empowering body positivity. To point the finger at social media of plastic surgeons as one cause of a complex problem is I believe oversimplistic and ignoring a much bigger issue. Body image anxieties are a real concern. It is frightening to learn of statistics from Prof Rumsey saying that 11 year olds are wanting cosmetic procedures. It is sad to learn that poor body image is one of the 3 biggest concerns of our young people. I worry how this will affect my children, as I do not want them to grow up with poor body image, like I did, and like so many of my patients who see me. Dissatisfaction about how one looks can affect one’s confidence, and can negatively impact on every aspect of one’s life. I know first hand seeing how many people don’t want to do something because they fear rejection, failure or disapproval because they lack self-worth and often it is linked to how they negatively see themselves and their appearance. But do our young people feel this way because what some plastic surgeons have posted on their social media feed? Let’s be real here, people feel this way because they live in a world where beautiful, sexy, attractive is celebrated and promoted EVERYWHERE – on TV, in magazines, on billboards, in shop windows – not just on social media. And coupled with the harsh reality that the world is cruel. Even without magazines and TV influencing our perceptions, fleeting or deliberate comments from other children, teenagers and adults whether innocent and unintentional or not, can and do crush self esteem and confidence. Being teased or being told you are fat and ugly or have a big nose or whatever, is enough to play on our minds, and sadly, has longevity. And this type of bullying about one’s appearance begins from such a young age, and I don’t think that is because of social media. I see children worried about their prominent ears because the kids at school are mean. I see some adults who have little to no confidence and they attribute that to being bullied when younger because they were overweight. Where are we learning to be so mean? Whatever happened to the adage, if you don’t have anything nice to say, don’t say anything at all. I grew up before social media when we all had varying degrees of dissatisfaction with our bodies merely because I believed we lived in a time where the supermodels Cindy, Claudia, Kate and Kristy and magazines like Dolly, Cleo and Cosmopolitan portrayed the notion that being beautiful, skinny, perfect were what we aspired to be like and if we didn’t we felt awkward and unattractive. Perhaps we didn’t all follow these models and magazines, but the problem of not feeling good about how we looked is age old. Centuries before women were wearing corsets to cinch in their waist so making them attractive to potential suitors looking for fertility in a woman. Wonder if women back then had body image issues? They probably had some dissatisfaction if they didn’t meet society’s view of attractive then but perhaps they never articulated it. Or maybe people were more tolerant and embracing of all shapes and sizes and appearances back then? Scientific studies have shown that people are drawn to features of beauty instinctively – and that doesn’t require influences externally. There is an argument that it is innate to be drawn to certain physical characteristics, and so whilst social media can certainly influence trends, as Kylie Jenner has in my mind, redefined the image of beauty, there is so much more to this problem of poor body image than can be blamed on plastic surgeons and social media. Add the era of the internet and social media and now everything is available online. But I do not believe it is what is splashed everywhere that has killed our body confidence, in as much as the culture where its ok to troll others, speak unkind words, be overly critical, be cruel and pass judgement on others that in my mind has fuelled body image anxieties. I am not a psychologist or sociologist and don’t claim to have the answers to a complex and concerning problem, but I do believe the onus is on society at large to change how we treat others and to start from a young age to foster tolerance, acceptance and values of kindness. As a plastic surgeon, we have a responsibility to be a part of the solution. I do believe that we already help so many patients find their self worth, love themselves more, become less self conscious and live their best lives. But we also need to make sure that we don’t set unrealistic, unattainable expectations for our patients, sexualise or trivialise what we do or make people feel worse about themselves so we can offer solutions to their problems. As members of the Australian Society of Plastic surgeons and Australasian Society of Aesthetic Plastic Surgeons, we need to advance the specialty of plastic surgery so we can help more people. We should work together with body image specialists to find solutions to fostering healthy positive body image in society, and ensure our social media and marketing is ethical realistic, professional and honest. For some people, finding one’s self worth may require counselling. For others it might be about career advancement. And some it might mean lifestyle changes. However there will always be some women and men who want to address a physical concern that holds them back from feeling good about themselves and achieving what they want to. This is equally valid, and articles and opinions that criticise or mock those of us who want to invest in ourselves and improve our appearance, do the opposite of helping us. They actually fuel even more angst. I am not claiming that plastic surgery fixes low body image. I am not arguing that if you don’t like something about your physical appearance then fix it and your woes will be over. I am not advocating that we should all go and get a boob job because the ones we saw on social media are amazing and if we don’t we will feel less of a person. Sorry for the dramatic sarcastic tone, but I am sick and tired of shaming those who want to do something for themselves. So long as the individuals have realistic expectations and are doing it for themselves and for the right reasons, it isn’t right to criticise them, or judge them as being superficial, vain, weak or any other negative undertones that some people automatically associate with plastic surgery. We don’t need to agree with their choices but we should learn to respect their autonomy in the very least. It would be my hope that we learn to be encouraging and supportive of each other rather than criticise and shame each other’s choices. I for one see women and men of all different age groups and from all walks of life who simply want to improve an area of their skin, face or body that bothers them and affects their confidence, happiness and freedom to be their best selves. In no way are these patients coming in feeling crap about themselves because they aspire to be like influencers. The overwhelming majority of my patients don’t want to be someone else – they only want to be the best version of themselves whatever age or stage of life they are at. Some have insecurities from a young age when someone teased them and that has stuck with them through most of their life. Some have insecurities that have formed from growing up in this society that is skewed in favour of who and what is beautiful. Many are going through key stages in their life when they want to feel good about themselves. Mums who feel frumpy and unattractive after having kids want to address their post-pregnancy body. Men and women who have left long term relationships want to regain their self confidence that a breakup has taken its toll on. Some want to not look aged so they can hang onto their jobs. Whetever the reason so long as it is for the patient who has realistic expectations, plastic surgery can be highly transformative, not only physically but also in how it translates positively to every aspect of one’s life. At the end of the day, social media is not going away and we cannot stop people looking and following Instagram accounts of those they relate to or engage with and search for what fits with their belief systems. For the surgeons who are posting risqué pictures labelled as “soft porn”, they are likely attracting patients who identify with those desired outcomes, but I know that my patients or those who follow me share the same values that I do about empowering others to be their best and kind self. Each to their own so long as we are not breaching professional and ethical guidelines, and not lumped into one basket as being part of a serious complex problem. With further collaboration and research, we can all be part of a solution. Natural medicine industry welcomes Wentworth victory for Dr Kerryn Phelps 2018-10-25T01:05:32Z natural-medicine-industry-welcomes-wentworth-victory-for-dr-kerryn-phelps-1 Media Announcement: 25 October 2018 Natural medicine industry welcomes Wentworth victory for Dr Kerryn Phelps The largest Australian body representing 10,000 natural medicine practitioners, The Australian Traditional-Medicine Society (ATMS), today welcomed the historic victory for Dr Kerryn Phelps on securing her seat in Wentworth following the by-election. Dr Phelps recently spoke at a Candidates Forum in Wentworth hosted by ATMS with Angela Vithoulkhas, Licia Heath and Shayne Higson. The candidates presented their positions on natural medicine, healthcare and small business with strong support from all candidates for complementary medicine, recognising its current role as a viable option for the health and wellbeing of Australians. ATMS are thrilled that Dr Phelps has gained the seat and support her principles of continued coverage of natural therapies within health funds, despite changes being implemented by the current Government. Charles Wurf, CEO, ATMS stated, “The election of a candidate who is supportive of complementary medicine is critical in this current environment seeking to remove subsidies for private health insurance. Further changes forecast by the recently announced Labor policy would seek to remove the GST exemption for naturopathy and herbal medicine treatments.” “ATMS maintains that restricting the choice of natural medicine treatments available within health insurance will prove a false economy. Policies targeted at limiting effective, proven natural medicine treatments will lead to greater pressure on public health and public hospitals,” finished Mr Wurf. ATMS looks forward to working with Dr Phelps and like-minded, committed Parliamentarians to ensure natural medicine treatments are available as effective, viable choices within the Australian healthcare and wellness system. To see how ATMS are representing natural medicine professionals in Australia, visit: www.atms.com.au -Ends- NOTES TO EDITORS: Interviews with: Charles Wurf, CEO, ATMS, are available on request through the below contacts For media enquiries please contact: Debbie Bradley, Group Account Director, Zadro P: 02 9212 7867 | debbie@zadroagency.com.au Sinead Andrews, Account Coordinator, Zadro P: 02 9212 7867 | sinead@zadroagency.com.au Image: Charles Wurf, CEO, ATMS About the Australian Traditional-Medicine Society: The Australian Traditional-Medicine Society (ATMS) is the leader of the natural medicine industry, promoting and representing professional practitioners of natural medicine, who are encouraged to pursue the highest ideals of professionalism in their natural medicine practice and education. As Australia’s largest national professional association for natural medicine practitioners, ATMS is a multi-disciplinary association representing over 10,000 accredited practitioners throughout Australia. ATMS was founded in 1984 and is an incorporated not-for-profit company. In 2014 ATMS celebrated their 30th anniversary representing natural medicine practitioners in Australia. ATMS is governed by a Board of Directors, with specialised departments for Massage Therapy, Chinese Medicine, Homeopathy, Nutrition, Naturopathy and Western Herbal Medicine. www.atms.com.au CannaTech Sydney Speakers & Topics 2018-10-23T07:58:28Z cannatech-sydney-speakers-topics Media Advisory CannaTech Sydney Speakers & Topics Showcasing Medical Cannabis Industry Thought Leaders in Business, Medical Science & Technology at Australia’s First Medical Cannabis Summit October 28-30 Tel Aviv & Sydney, Oct. 23, 2018…CannaTech Sydney, Australia’s first ever Medical Cannabis Summit will highlight the biggest industry thought leaders known for their significant and ground-breaking contributions to the exploding global cannabis market in all fields. CannaTech covers a wide breadth of the most current industry topics agenda including presentations that cover Medical Science, Technology, Investment, International Regulation and more. Participants from around the world will gather at Doltone House, Darling Island. The summit will be preceded on October 28 by a special Cannabis Business Symposium. Journalists and photographers must register in advance! NOTE: There will be an on-site PRESS BRIEFING with CannaTech CEO Saul Kaye and several top international and Australian medical cannabis leaders on Monday, October 29, 11:15-11:45 am. Check with registration desk to confirm location. Following is a schedule of topics and speakers. Schedule subject to change. Sunday September 28, Business Symposium 14:00 - 14:30 Global Investment Trends and Forecasts: A Macro Assessment of the APAC Cannabis Market John Kagia/ Chief Knowledge Officer, Industry Analytics, New Frontier Data 14:30 - 15:00 Business Keynote: Making Sense of the Surging Global Cannabis Market Bruce Linton, Founder, Chairman and Co-CEO, Canopy Growth 15:00 - 15:30 How to Stay Competitive in an Expanding Global Market (the branding & marketing of medical cannabis) Brad Gobel, Director of Regulated Industries, Shopify Chris-Driessen, Partner; President, Organa Brands U.S. Jeremy-Heid, Co-Founder; President, Organa Brands International 15:30 - 16:00 Cannabusiness and Academia; Building for the Next Generation Nitin Mantri, Associate Professor, RMIT University Ron Lipsky, VP of Business Development, MGC Pharma 16:30 - 16:50 Going Global: Cannabis Business Opportunities in Latin America Alfredo Pascual, International Analyst, Marijuana Business Daily 16:50 - 17:00 Wholesale Cannabis Merchant Trading Platform Experience Saul Singer, Co-Founder & CEO of CMTREX 17:00 - 17:30 An In-depth Look at European Medical Cannabis 17:30 - 17:45 Constance Finley, Founder and CEO, Constance Therapeutics 17:45 - 18:15 Regulation’s Role in Global Partnerships & Cannabis Business Decisions Deepak Anand, VP, Business Development & Government Relations, Cannabis Compliance Inc. Pat McCutcheon, President and CEO, MediPharm Elaine Darby, Managing Director, AusCann Group Holdings Ltd Lynn Honderd, Co-Founder & CEO, Mary 18:15 - 18:45 Panel: Capital Market, The How and Why of Going Public Stephen Silver/ Managing Director, Hunter Capital Advisors Director, Capital Markets, TheraCann International Benchmark Corporation Jeremy Leibler, Partner, Arnold Bloch Leibler 18:45 - 19:00 Cannabis Investment Overview: Fear, Risk & How to Spot a Winner Brian Sheng, General Partner, Arcview Group 19:00 Closing Remarks Saul Kaye, CEO, Founder of iCAN: israel cannabis Monday, October 29, Summit Day 1 9:30 - 09:45 Lorne Gertner, Chairman & Co-Founder, Hiku Brands Company Ltd. Helen Kapalos, Chairperson, Victorian Multicultural Commission 09:45 - 10:00 The Ethnopharmacological History of Cannabis Justin Sinclair, Research Fellow, NICM 10:00 - 10:30 Policy & Regulation Panel: Getting on the Map in Global Medical Cannabis Policy and Next Steps for Australia Deepak Anand, VP, Business Development & Government Relations, Cannabis Compliance Inc. Mimi Busk Downey, Director of Regulatory Affairs, TheraCann International Benchmark Corporation Jonathan Zaid, Director of Advocacy and Corporate Social Responsibility, Aurora Carol Ireland, CEO and Managing Director, Epilepsy Action Australia 10:30 - 10:45 Humans of Medical Cannabis: The Road to 'Rylie's Law' Rylie Maedler, President & Founder, Rylie's Sunshine 10:45 - 11:15 Pharma 2.0 – Exploring the Development of Cannabis as Medicine Dr. Guy Chamberland, CSO & Regulatory Affairs, Tetra Bio-Pharma Constance Finley, Founder and CEO, Constance Therapeutics Sharlene Mavor, Medical Cannabis Research Australia (NFO) Dr. Melanie Kelly, Professor, Dalhousie University, Canada 11:45 - 12:00 Macro Trends on Global Cannabis Market (Including CBD) Giadha Decarcer, Founder & CEO, New Frontier Data 12:00 - 12:30 All Star Canadian Panel Vinay Tolia/ CEO, The Flowr Joshua Eades, Vice President, Chief Science Officer, Tilray Pradyum Sekar, CEO, Sail Cannabis 12:30 - 12:45 Beyond Physician and Patient Education Pradyum Sekar, CEO, Sail Cannabis 12:45 - 13:15 Global Insights Panel Cam Battley, Chief Corporate Officer, Aurora Cannabis Dr. Stewart Washer, VP Business Development, AusCann Ltd 13:15 - 13:30 Nutraceutical, Cannaceutical, and Pharmaceutical Stephane Redey, Scientific Industry Advisor, PhD, Creso Pharma 14:30 - 15:00 Effecting Change: The Advocates' Road to Compassionate Care Alice Oleary Randall, Medical Cannabis Pioneer, Editor-in-Chief, Mary's Lucy Haslam, Executive Director, Co-Founder, United in Compassion Lynn Honderd, Co-Founder & CEO, Mary 15:00 - 15:15 Cannabis & Cancer Research Prof. Marco Falasca, Professor, School of Pharmacy and Biomedical Sciences, Curtin University 15:15 - 15:30 The PELICAN study: Results and Implications for Policy Anastasia Suraev, Clinical Research Officer, Lambert Initiative for Cannabinoid Therapeutics 15:30 - 15:50 Australia’s First Producer Fleta Solomon, Managing Director, Little Green Pharma 15:45 - 16:05 Navigating Australia’s Cannabis Landscape Paul Mavor, Director, Health House and Medical Cannabis Research Australia 16:05 - 16:30 Using Microbes in Commercial Cannabis Cultivation Colin Bell, Chief Growth Officer, Growcentia Tuesday October 30, Summit Day 2 09:30 - 9:45 Next Gen Research: Clinical Research Programs Including Soon-to-be-Published Driving Data Prof Iain McGregor, Academic Director, Lambert Initiative for Cannabinoid Therapeutics 09:45 - 10:10 The Methodology of Studying and Doing Cannabis Research Dy. Ryan Vandrey, Associate Professor, Johns Hopkins University 10:10 - 10:35 The Regulation of the Cultivation and Manufacture of Medicinal Cannabis Products John Skerritt, Adjunct Prof FTSE FIPAA (Vic), Deputy Secretary, Department of Health, Australia 10:35 - 10:55 Chemotype Variance and the Relation to Clinical Health Outcomes Andrew Samann, CEO and Founder, Orion GMP Solutions 11:00 - 11:15 Potential of Cannabis-Based Medicines to Treat Psychiatric Illness and Improve Brain Health Dr. Katrina Green, Researcher, Lecturer, University of Wollongong 11:45 - 12:00 From Hemp to Cannabis: Around the World in Two Decades Paul Benhaim, Executive Director and CEO, Elixinol Global Limited 12:00 - 12:15 Expert Research on Cannabis for Epilepsy Prof. Uri Kramer, Scientific Advisor, MGC Pharma 12:15 - 12:30 Medical Research: Cancer and Full-spectrum Products, CBD:THC Synergy and Pain Jonathan Arnold, Associate Professor, Lambert Initiative for Cannabinoid Therapeutics 12:30 - 12:50 T​he Education and Administration of Medical Cannabis Treatment for Paediatric Care Naama Saban, RN BcS, Medifarm 12:50 - 13:10 Patient Centric Consumer Trends: Canadian Data Tells the Story Matei Olaru, CEO, Lift & Co. 13:10 - 13:30 Health, Science and Policy: A Patient First Agenda Dr. Mark Ware, Chief Medical Officer, Canopy Growth 14:30 - 14:50 The Importance of Maintaining an Honest Business Charles Feldmann, Head of International Cannabis Team, Cantafio Feldmann Nagel 14:50 - 15:10 Ensuring a Reliable, Economic, Practical and Safe Cannabis Regulatory Framework Chris Bolton, COO and Founder, TheraCann International Benchmark Corporation 15:10 - 15:30 Lessons from Canada: Medical Education and the Road Forward for Medical Cannabis in Australia Daniel Schecter, Co-founder & Medical Director of the Canadian Cannabinoid Medical Clinic 16:00 - 16:15 Science & Medicine: Next Steps in Cannabis Extraction Technology Pat-McCutcheon, President and CEO, MediPharm Labs 16:30 - 17:00 3 Under 30: The Future of Australian Medical Cannabis Adam Miller, Founder and CEO, BuddingTech Rhys Cohen/ Project Officer, Lambert Initiative for Cannabinoid Therapeutics Australian Media Contact for interviews, media enquiries and registration: Candice Meisels candice@candicepr.com To register and for further information contact Laura Kam, laura@kamgs.com, 972-54-806-8613. CannaTech Announces Platinum Sponsorships for CannaTech Sydney, Australia’s First Ever Medical Cannabis Conference, October 28-30 2018-10-15T22:18:14Z cannatech-announces-platinum-sponsorships-for-cannatech-sydney-australias-first-ever-medical-cannabis-conference-october-28-30 CannaTech Announces Platinum Sponsorships for CannaTech Sydney, Australia’s First Ever Medical Cannabis Conference, October 28-30 Spectrum, New Frontier Data, MGC Pharma and Theracann will be attending and sponsoring the CannaTech event Tel Aviv & Sydney, October 16, 2018…CannaTech, the creator of the world’s premier cannabis events, is pleased to announce its Platinum Sponsorships for CannaTech Sydney, Australia’s first ever Medical Cannabis Summit taking place October 28-30, 2018 in Sydney. Saul Kaye, Founder and CEO of CannaTech and iCAN: Israel Cannabis issued the following statement: "We are thrilled that these companies are the leading sponsors of CannaTech Sydney and greatly appreciate their support. Australia and the APAC region are an exciting and growing medical cannabis market and we value the participation of these top companies which will help shine a light on this emerging industry. Each of these companies bring unique and ground-breaking expertise to CannaTech and we look forward to having them share their in-depth knowledge with our audience which will hail from the Continent and around the world. " Spectrum Cannabis is the new Australian branch of Canopy Growth, the world’s largest publicly traded cannabis company currently worth over $15 billion (USD). New Frontier Data is the leader in providing unbiased vetted information to stakeholders in the global cannabis industry. The will be providing data on the medical cannabis industry in Australia as well as on Hemp and CBD in China, Hong Kong and Asia. MCG Pharma, an Australian company that recently received a significant $1,000,000 (USD) investment from CannaGlobal, solidifying its place as Australia’s leading cannabis wellness and lifestyle products business. TheraCann International provides business, technology and industry experts who apply advanced technology to help clients design, build and run their cannabis businesses. We are all looking forward to CannaTech Sydney to move the industry forward and, most importantly, help patients throughout the continent and region. The CannaTech Sydney Summit will cover the most current industry topics including Ag Tech & Innovation, Business & Finance, Policy & Regulation, Science & Medicine. Human interest stories will be an important component of the program. The summit will take place at Doltone House Darling Island Wharf. Click here for list of CannaTech Sydney speakers and daily schedule. About iCAN: Israel-Cannabis iCAN is building the global cannabis ecosystem. iCAN identifies and accelerates innovative medical cannabis technologies and creates synergies and cooperation across the industry. iCAN uses its global network and reach to position Israel as the leading medical cannabis tech hub. About CannaTech CannaTech is powered by iCAN. CannaTech is the premier international cannabis summit held annually in Tel Aviv, and internationally in London, Panama, and for the first time in Sydney, Australia in October 2018 and Hong Kong in November 2018. For further information, media inquiries and journalist registration contact: Candice Meisels candice@candicepr.com G MEDICAL ENGAGES US UNDERWRITER TO MANAGE DUAL-LISTING ON NASDAQ 2018-10-01T23:22:12Z g-medical-engages-us-underwriter-to-manage-dual-listing-on-nasdaq October 2, 2018 – Sydney, AUSTRALIA - Mobile and e-Health company G Medical Innovations (ASX: GMV) (“G Medical” or the “Company”) has today engaged a New York based Underwriter, to assist in the processes towards a US Public Offering via the NASDAQ Stock Exchange. The Company will remain listed on the Australian Stock Exchange, and the management of G Medical have engaged an Underwriter who will now proceed with submission of the F-1 Registration Statement with all parties working towards a US listing within the next 4 to 5 months. G Medical cautions investors that there can be no certainty that the proposed US listing will proceed. Investors should note that the listing is subject to satisfaction of all legal and regulatory requirements with NASDAQ, SEC and ASX, as well as any shareholder approvals that may be required under the ASX Listing Rules. Shareholders will be updated throughout the process as appropriate, and the amount of capital to be raised will be determined closer to the proposed offering. -ENDS- Corporate Advisors Otsana Capital 108 Outram Street West Perth WA 6005 Telephone: +61 8 9486 7244 www.otsana.com Investor Relations Viriathus Australia Level 8/525 Flinders Street Melbourne VIC 3000 Telephone: +61 2 8667 5360 www.viriathus.com Media Enquiries Closer Communications David Wolf Telephone: + 61 411 111 787 david@closer.com.au About G Medical Innovations G Medical (ASX: GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity. The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories. For more information on G Medical, please visit www.gmedinnovations.com IMC19 brings the future of science into focus 2018-09-25T22:43:44Z imc19-brings-the-future-of-science-into-focus-1 Critical discoveries and research that will help to transform health, science and industry are set to be the lasting legacy of the 19th International Microscopy Congress (IMC19), according to leaders of the scientific world. Held every four years, IMC19 saw more than 2,100 of the world’s top scientists and researchers from 48 countries come together at ICC Sydney to network, collaborate and discover the latest high-tech instrumentation and systems in microscopy and microanalysis. IMC19 also inspired the next generation of young scientists with its Schools Outreach Program, which welcomed 570 students from 19 schools. The program also featured a “Young Scientists Assembly” where 50 young scientists from around the world enjoyed the opportunity to discuss career planning with some of the most senior figures in the field. Professor Simon Ringer, Congress Chair, said the impact of IMC19 would be revealed over time from the global scientific community. “Innovations in microscopy enable us to extend our understanding of ourselves and the world around us. IMC19 brought together leaders in both the development and the application of microscopy in a huge range of disciplines,” he said. “These connections will ultimately lead to breakthroughs, as researchers take the insights from advanced microscopy to develop a treatment for cancer, a vaccine for a virus, or a new 3D printed metallurgical alloy that improves our atmosphere by being strong and light and thereby fuel and greenhouse gas efficient.” The week-long scientific program included presentations by four expert plenary speakers, two Nobel Laureates, 150 invited presenters as well as 26 pre-congress workshops and 463 oral talks, bridging the primary streams of Frontier Issues; Instrumentation and Techniques; Physical and Life Sciences. The pioneering IMC19 Outreach Learning Program welcomed high school students to experience the very latest light and electron microscope equipment and a chance to meet with researchers and specialists in microscopy. Mrs Diane Fairweather, Head of Science, Riverstone High School, said the program allowed students to access cutting-edge technology. “This was a great STEM initiative by IMC19 and an amazing experience for the students who came. We don’t have these microscopes at our school and without the IMC19 Outreach Program, most of our students wouldn’t be able to use this equipment,” said Fairweather. “Our students are engaged; they are learning directly from experts on things like using the lens to focus – it’s a real hands-on experience.” The Outreach Program offered students access to the latest equipment including, VR, four scanning electron microscopes, 20 life microscopes and 3D printing. Equipment and demonstrations were supported by Zeiss, Leica, AXT, Keepad Interactive, NewSpec, ATA, Coherent, UNSW Art and Design and Me3D. Citing recent examples of some of the life-changing advancements that have developed as a direct result of microscopy, Dr Alan Finkel, Australia’s Chief Scientist, inspired the audience at IMC19 and set the scene for a week of breakthroughs in his opening address. “An investment in this field (microscopy) is an investment in nanoparticles that target such things as a drug directly to malignant cells; 3D printed lattices that act like tiny factories for T-cells; vital in the new generation of cancer immunotherapies and more,” said Dr Finkel. “Without Microscopy, there is no modern science – end of story.” Professor Paul Munroe, Congress Co-Chair, said IMC19 had laid the foundations for great things. “We are excited to see where the collaborations from IMC19 take the industry, and what new technology and research will be showcased at the next congress in Korea in 2022,” he said. For more information on IMC19 visit: http://imc19.com. IMC19 brings the future of science into focus 2018-09-25T22:34:39Z imc19-brings-the-future-of-science-into-focus Critical discoveries and research that will help to transform health, science and industry are set to be the lasting legacy of the 19th International Microscopy Congress (IMC19), according to leaders of the scientific world. Held every four years, IMC19 saw more than 2,100 of the world’s top scientists and researchers from 48 countries come together at ICC Sydney to network, collaborate and discover the latest high-tech instrumentation and systems in microscopy and microanalysis. IMC19 also inspired the next generation of young scientists with its Schools Outreach Program, which welcomed 570 students from 19 schools. The program also featured a “Young Scientists Assembly” where 50 young scientists from around the world enjoyed the opportunity to discuss career planning with some of the most senior figures in the field. Professor Simon Ringer, Congress Chair, said the impact of IMC19 would be revealed over time from the global scientific community. “Innovations in microscopy enable us to extend our understanding of ourselves and the world around us. IMC19 brought together leaders in both the development and the application of microscopy in a huge range of disciplines” he said. “These connections will ultimately lead to breakthroughs, as researchers take the insights from advanced microscopy to develop a treatment for cancer, a vaccine for a virus, or a new 3D printed metallurgical alloy that improves our atmosphere by being strong and light and thereby fuel and greenhouse gas efficient.” The week-long scientific program included presentations by four expert plenary speakers, two Nobel Laureates, 150 invited presenters as well as 26 pre-congress workshops and 463 oral talks, bridging the primary streams of Frontier Issues; Instrumentation and Techniques; Physical and Life Sciences. The pioneering IMC19 Outreach Learning Program welcomed high school students to experience the very latest light and electron microscope equipment and a chance to meet with researchers and specialists in microscopy. Mrs Diane Fairweather, Head of Science, Riverstone Highschool, said the program allowed students to access cutting-edge technology. “This was a great STEM initiative by IMC19 and an amazing experience for the students who came. We don’t have these microscopes at our school and without the IMC19 Outreach Program, most of our students wouldn’t be able to use this equipment,” said Fairweather. “Our students are engaged; they are learning directly from experts on things like using the lens to focus – it’s a real hands-on experience.” The Outreach Program offered students access to the latest equipment including, VR, four scanning electron microscopes, 20 life microscopes and 3D printing. Equipment and demonstrations were supported by Zeiss, Leica, AXT, Keepad Interactive, NewSpec, ATA, Coherent, UNSW Art and Design and Me3D. Citing recent examples of some of the life-changing advancements that have developed as a direct result of microscopy, Dr Alan Finkel, Australia’s Chief Scientist, inspired the audience at IMC19 and set the scene for a week of breakthroughs in his opening address. “An investment in this field (microscopy) is an investment in nanoparticles that target such things as a drug directly to malignant cells; 3D printed lattices that act like tiny factories for T-cells; vital in the new generation of cancer immunotherapies and more,” said Dr Finkel. “Without Microscopy, there is no modern science – end of story.” Professor Paul Munroe, Congress Co-Chair, said IMC19 had laid the foundations for great things. “We are excited to see where the collaborations from IMC19 take the industry, and what new technology and research will be showcased at the next congress in Korea in 2022,” he said. For more information on IMC19 visit: http://imc19.com. Images: IMC19 Outreach Learning Program: Notes to editors: Interviews with Professor Simon Ringer, Congress Chair, IMC19 Interviews with Professor Paul Munroe, Congress Co-Chair, IMC 19 Media enquires contact Zadro Sinead Andrews | Account Coordinator | Zadro 02 9212 7867 | sinead@zadroagency.com.au Elizabeth Williams | Group Account Director | Zadro 02 9212 7867 | elizabeth@zadroagency.com.au NOTE: About the 19th International Microscopy Congress, 9 – 14 September 2018 Held once every four years, the International Microscopy Congress (IMC) is the preeminent meeting for researchers, practitioners, decision makers, national microscopy societies, industry partners and stakeholders involved in microscopy sciences from all over the world. Now in its 19th year, IMC19 ‘Microscopy: Bridging the Sciences’ is the only platform to bring together international, national and local professionals to discover new opportunities, uncover findings, learn techniques, collaborate with peers, and network with global leaders in the field of microscopy. About the Australian Microscopy & Microanalysis Society (AMMS) The Australian Microscopy & Microanalysis Society (AMMS) is Australia’s industry association for the promotion, co-operation and development of microscopy, microanalysis, and related techniques across a broad range of scientific disciplines. About the International Federation of Societies for Microscopy (IFSM) The International Federation of Societies for Microscopy (IFSM) comprises microscopy societies from all around the world to contribute to the advancement of microscopy in all its aspects. Microscope that gets to the heart of matter 2018-09-10T03:41:58Z microscope-that-gets-to-the-heart-of-matter Two Nobel Laureates and the NSW Chief Scientist & Engineer will officially unveil a vital piece of scientific infrastructure at the University of Sydney at a special event. The Thermo Fisher Themis-Z transmission electron microscope (TEM) has the highest resolution of any microscope in Australia. Its addition to the University of Sydney will provide researchers with unparalleled access to the mysteries of the atomic structure of materials. The 4.5-metre tall microscope is housed in the purpose-built $150 million Sydney Nanoscience Hub in a room that is shielded from electromagnetic interferences and ‘floats’ architecturally independent from the building to minimise vibrations. The resolution of this analysis technique is breathtaking. The machine can obtain images with resolution better than 0.06 billionths of a metre (0.06 nanometres). That is about 10 times smaller than the distance between silicon atoms or five times smaller than the distance between carbon atoms in diamond. The microscope, which is available for industry as well, also has applications in geosciences, mining, chemical and mechanical engineering. The new NSW Chief Scientist & Engineer, Professor Hugh Durrant-Whyte will unveil the device in his first week of his official functions alongside two Nobel Laureates in Chemistry, Prof. Dan Shechtman, The Technion, Israel and Professor Joachim Frank, Columbia University, USA, who are visiting Sydney for the 19th International Microscopy Congress (IMC19), which is jointly hosted by the University of Sydney and UNSW. Event details: What: Sydney Microscopy and Microanalysis launch event Aberration-corrected Transmission Electron Microscope Where: Research Foyer, Sydney Nanoscience Hub, Physics Road, University of Sydney When: Tuesday, 11 September 2018. 1.45pm for 2pm start. The 19th International Microscopy Congress (IMC19), 9-14 September, at ICC Sydney, will centre around the theme, Microscopy: Bridging the Sciences, promoting collaboration across the primary streams of Frontier Issues; Instrumentation and Techniques; Physical and Life Sciences. Complimentary media passes to the launch event are available; apply by sending your name, position and publication title to sinead@zadroagency.com.au. Complimentary media passes to IMC19 are also available; apply by sending your name, position and publication title to sinead@zadroagency.com.au. Image: The Thermo Fisher Themis-Z transmission electron microscope (TEM) One of Australia's leading Plastic Surgeon's issues warning to Mums thinking about Mummy Makeover Surgery Holidays 2018-09-06T22:07:33Z one-of-australias-leading-plastic-surgeons-issues-warning-to-mums-thinking-about-mummy-makeover-surgery-holidays One of Australia's leading Plastic Surgeon's issues warning to Mums thinking about Mummy Makeover Surgery Holidays Many Mums use the Summer Holidays for discreet nip and tucks on Medical Holidays Press Release For Immediate Release Darling Point, Sydney, Australia, 7th September 2018, after pregnancy and breastfeeding, many Australian Mums feel unhappy with the look of their post-natal bodies. Many hit the gym and eat healthy to try and get their pre-pregnancy figures back. Some Mums look at cosmetic surgery options available to them and are lured by medical holidays which offer holidays for their families including kids club for the kids and nip and tucks for Mums. Internationally renowned and Triple board certified, leading Sydney Plastic Surgeon, Dr. Ross Farhadieh, states: “We have just seen yet another tragic news of a young woman dying during cosmetic medical tourism brought out the real and ever-present dangers of these so called “medical holidays”. A young British mother met her demise following a Brazilian Butt Lift (BBL) Surgery. This is a procedure where unwanted fat is harvested from other parts of the body and after processing, is reinjected into the buttocks to give definition and re-inflate, a deflated and sagging posterior. In some cases, it’s actually used to over-inflate the backend to achieve an exaggerated prominence. Recently, the American Society of Plastic Surgery, International Society of Aesthetic Plastic Surgery, as well as, the American Society of Aesthetic Plastic Surgery have all issued warnings about this procedure.“ Cosmetic surgery is elective and usually safe surgery with mortality rates being recorded as low as 1:55000, this is in contrast to BBL surgery which has now been documented to have unacceptably high rates of mortality approaching 1:3000. In all cases that were investigated it became clear that fat had entered the blood stream and resulted in what is called a “Fat embolus”. This is something usually seen in major orthopaedic surgery of the long bones, where bone marrow fat is forced into the circulation ending in the lungs. The resulting cascade of inflammatory reactions culminates in the ultimate death of patients. The reason overseas options are cheaper is due to a myriad of factors, lower medical standards, less safety nets, lower labor costs, lower senior and support staff qualifications, no medical insurance and the list goes on. These are many layers of safety built into our medical system over the years to ensure the safest and most optimal outcome for patients. These layers upon layers of safety also do translate into an increased cost, but more importantly continued and outstanding after care and safety net should there be any problems. Dr Farhadieh says: “As a plastic surgeon I have seen too many young mums who have returned home with their own nightmares of botched plastic surgery. Belly buttons a few centimeters off center, lopsided breasts with double bubble deformities, poor breast implant placement, poorly and inappropriately placed scars. Surgical journey nightmares that seem unending, with expensive revision surgeries at home that will never achieve the optimal outcome, had the primary surgery been successfully and appropriately carried out. “ “All too often the postoperative support for medical tourism is nonexistent at home and cursory overseas. What happens if there is a problem when you arrive back home? Who is to take care of the potential complications? These are serious and pertinent questions that have to be answered when considering medical tourism. “ Well-equipped Australian hospitals and appropriately qualified Plastic Surgeons provide the safest options for any aesthetic surgery procedure. Dr Farhadieh says “The holidays are the perfect time for facial aesthetic surgery, facelift surgery, neck lift surgery, eyelids surgery or that nose job that folks have been thinking about for some time are discreetly done over the break and by the time they return to work the only tell-tale is comments of work colleagues and friends about looking "refreshed and rested”. “ Media Contact: Candice Meisels candice@candicepr.com 0481 369 484 About Dr Ross Farhadieh: Dr Ross Farhadieh is an internationally renowned Australian trained and qualified cosmetic plastic and reconstructive surgeon. He is triple board certified. There are less than a handful of plastic surgeons in the World who have three board certifications. Dr Farhadieh is the Chief Editor of the critically acclaimed and internationally hailed reference textbook of plastic surgery: Plastic & Reconstructive Surgery: Approaches and Techniques. His own contributions were chapters on breast augmentation, eyelid and facelift surgery. Dr Farhadieh is a keen runner, with an unrivalled running music playlist to keep him motivated. He is a voracious reader and is particularly interested in history and philosophy. He has a passion for Renaissance art, Italian food, and French wine. He also enjoys travelling, particularly in Europe. Above all, he loves spending time with his wife and young son. https://www.panthea.com.au/ How many scientists does it take to look through a microscope? 2018-09-06T02:03:09Z how-many-scientists-does-it-take-to-look-through-a-microscope More than 2,000 of the world’s top scientific brains will explore new findings, share research, and experience the latest state-of-the-art scientific microscopy equipment helping to reinvent and expand human knowledge, in Sydney next week. Field emission guns and new electron exploration systems are two of the many innovations and leading advancements in medical science that will be on show when the world’s largest microscopic community descends on Sydney for the 19th International Microscopy Congress (IMC19). The event, held every four years, starts on 9 September and will see presentations by world-renowned thought leaders and Nobel Laureates Professor Dan Shechtman and Professor Joachim Frank, from The Technion Israel, who won the 2017 Nobel Prize in chemistry for his work as founder of the single-particle cryo-electron microscopy (cryo-EM). By bringing together experts working across a multitude of academic and industrial fields, IMC19 will showcase - and define - how clear, crisp microscopic magnification, helps advance life on Earth. The genesis of our future’s most significant discoveries including reproductive breakthroughs and a step towards a cure for cancer can be found at this world-famous science event and the multi-million-dollar equipment on display. Tek-Event, Sydney based manufacturer of equipment dedicated to the field of human and animal reproductive technologies (ART), will showcase its range of brand new technologies providing a safe environment for tissue observation. Dieter Regel, Sales Director, Tek-Event, commented on the increasing requirement to provide accurate temperature control as well as CO2 and humidity in the latest technologies advancing human IVF laboratories, animal research and veterinary ART facilities. “Researchers who have the requirement to view cells or tissue microscopically, are often challenged when their environment is not stable. TEK-Event are excited to showcase our latest Cell-Tek microscope chambers, which helps create a controlled environment for examination in many fields of research, including the handling of oocytes and embryos in ART,” said Regel. Thermo Fisher Scientific will offer attendees a chance to take part in live demonstrations with technical experts working in innovative software and automated microscopy products and showcase a wide range of microscopy solutions. Attendees can register for a learning lunch with ZEISS, to experience their innovative microscopy technologies and applications. Sessions will cover 3D electron microscopy; X-ray microscopy and analytical microscopy and guests can win a ZEISS VR One Plus virtual reality headset. Tek-Event, Thermo Fisher Scientific and ZEISS will be joined by over 60 other confirmed exhibitors at IMC19, including Jeol, Quorum Technologies, Tescan, Technoorg Linda Co Ltd, Delmic, Hitachi, Leica and Nano Technologies Solutions. Delegates will also enjoy a range of activities and a vibrant social program in conjunction with the congress, aimed to engage attendees and help spark new connections among the scientific community. The IMC19 Outreach Learning Program will host 21 schools across Australia, to offer students the chance to undertake four storyline-based challenges, featuring the latest light and microscopy equipment alongside leading researchers and instrument specialists. Microscopy Australia will present a unique exhibition during the congress, Stories & Structures - New Connections, bringing together microscopy and Indigenous art through visual and story-telling parallels. The exhibition will showcase 21 artworks and 24 micrographs, as well as feature live painting by Indigenous artist Kurun Warun in residence. The 19th International Microscopy Congress (IMC19), 9-14 September, at ICC Sydney, will centre around the theme, Microscopy: Bridging the Sciences, promoting collaboration across the primary streams of Frontier Issues; Instrumentation and Techniques; Physical and Life Sciences. From a one-woman business to a national Business Excellence Award 2018-09-05T03:28:33Z from-a-one-woman-business-to-a-national-business-excellence-award Press Release For Immediate Release From a one-woman business to a national Business Excellence Award Northern Beaches, Sydney, 5th September 2018, Emma McNeilly, founder of Expressions Australia took home the Business Excellence Award at The AusMumpreneur Awards which were held last Friday night, the 31st of August, in Melbourne. Emma started as a one-woman operation, working with a handful of schools and now, Expressions has grown into a national brand and trusted name in the fundraising industry. Emma says: “Expressions is Australia’s most loved tea towel fundraising company. We began in 1999 as a one-woman operation and have grown into a thriving business of working women who are proud to help raise funds for community organisations across Australia.” To date Expressions has worked on over 18,500 community fundraising projects, helping raise millions of dollars for schools and community groups in every corner of Australia. The products bring an easy, creative and sugar-free solution to vital school and community fundraising. Emma adds “We have close to 3 million tea towels, aprons and bags in kitchens and keepsake boxes in every corner of Australia and around the world. Over 1300 schools and childcare centres trust us each year with their precious artwork, ranging from large city schools to tiny remote communities.” “To accomplish this, I employ a team of 5 people to manage different aspects of the business, we have embraced the effective use of digital and online technologies which allows us to work together nationally between Sydney, Margaret River in WA, Tasmania and Burleigh Heads in SW QLD.” “Expressions provides a win for everyone involved at every stage of the process. Funds raised, proud children, delighted clients and a healthy business. The tea towels are celebratory and inclusive, and the business has a genuine feel good factor. The sentimentality of children being surrounded by their friends and favourite teachers creates a warm and fuzzy for all, they have become a tradition for so many of our clients.” “We really focus on customer service, and I understand from first had experience how precious volunteer’s hours are. Fundraising plays a vital role for grass roots communities, so we strive to ensure our projects are easy to run, everything is supplied, and in turn everybody loves them.” “We have thousands of glowing testimonials. A testament to our service is a near perfect Net Promoter score. Half of our annual workload is repeat bookings and hundreds of Coordinators and organisations have worked with us over many years. Our practical products make a lasting memento and the designs encompass a real sense of community, so they sell well for our clients.” Peace Mitchell, Co-Founder, AusMumpreneur Network states: “We are delighted that Emma has won this award, she has created an outstanding business and is an inspirational role model and ambassador for mums in business everywhere.” Emma has worked in fundraising for over 20 years and has served as a volunteer on many committees for 15 years. She has a rich understanding of the very important and far reaching world of vital community fundraising from both sides of the fence. Emma is now taking that wealth of experience and has formed a niche communications agency - Progeny Communications - which brings brands together with Australia's most powerful consumer, Mums. Emma concludes “Mothers are making the purchasing decisions for most of Australia's households and we are connecting with them, where they are – right at the heart of grassroots communities.” Emma’s Tips for other Small to Medium Size Businesses: - Put the customer at the forefront of all your business decisions, put yourself in their shoes and plan from there. - Document all your procedures so it’s easy to train, then hire people that are better at something than you are and let them do their job. - It’s Ok to ask for help – the key to balance for me was learning to let go and embracing the art of delegation. - In the business or at home, outsource if you can, hire a cleaner, engage a bookkeeper, whatever works. There’s lots of talented people out there, so when and if you can, share the load. ENDS Media Contact: Candice Meisels candice@candicepr.com - https://www.expressions.com.au/ G MEDICAL ENGAGES GLOBAL INVESTMENT BANK ‘UOB’ FOR PROPOSED LISTING OF CHINESE SUBSIDIARY ON MAIN BOARD OF HONG KONG STOCK EXCHANGE 2018-08-07T23:56:44Z g-medical-engages-global-investment-bank-uob-for-proposed-listing-of-chinese-subsidiary-on-main-board-of-hong-kong-stock-exchange Highlights: G Medical engages Global Investment Bank, UOB Kay Hian (Hong Kong) Ltd, as advisors to Hong Kong Initial Public Offering of its Chinese subsidiary Initial market capitalisation to be at least HK$1,500,000,000 (~A$260 million), as required by HKSE Listing Rules Mobile and e-Health company G Medical Innovations (ASX: GMV) (“G Medical” or the “Company”) has today announced its plan to list its Chinese subsidiary, Guangzhou Yimei Innovative Medical Science and Technology Co. Ltd, on the main board of The Stock Exchange of Hong Kong Limited (“Hong Kong Stock Exchange” or “HKSE”). Under the proposed listing, Guangzhou Yimei Innovative Medical Science and Technology Co., Ltd (“GYIMSTC Ltd”) would spin off from G Medical, with the Australian Securities Exchange Ltd (“ASX”) listed G Medical (“Parent Co”) to retain not less than a 50% ownership stake in the proposed Hong Kong Stock Exchange listed GYIMSTC Ltd. G Medical Parent Co currently owns 70% of GYIMSTC Ltd. The management of G Medical have appointed global Investment Bank, UOB Kay Hian (Hong Kong) Limited (“UOB”) to act as the financial adviser (the “Agreement”). UOB have committed to the proposed IPO in accordance with all minimum listing requirements of HKSE, with all parties working towards a listing within the next 6 to 9 months. G Medical cautions investors that there can be no certainty that the proposed IPO will proceed, and that the listing is subject to satisfaction of all legal and regulatory requirements in Australia and Hong Kong, including any shareholder approval that may be required under the ASX Listing Rules. Shareholders will be updated throughout the process as appropriate. Guangzhou Yimei Innovative Medical Science and Technology Co. Ltd oversees all China-based manufacturing for G Medical, ensures all local certifications are met, and has worked to build a strong relationship with the China Food and Drug Administration (CFDA). It was the first company in 2018 to be granted acceptance to the Green Channel expedited Guangdong Provincial CFDA regulatory approval process. This process was successfully applied to G Medical’s Prizma Medical Smartphone Case, and will play a crucial role in the global commercialisation of this product. Future innovative medical solutions currently in the development pipeline should also benefit from this process. Green Channel also ensures expedited future CFDA applications and delivers a reduction in local enterprise income tax from 25% down to 15%. Funds raised from this listing will provide substantial working capital and fuel the research and development of innovative mobile health solutions and enable continued investment into state-of-the-art manufacturing facilities. The amount of capital to be raised will be determined closer to the proposed IPO. Under the terms of the Agreement, UOB will obtain an in-principle approval from the Hong Kong Stock Exchange to proceed with the listing application, with the initial market capitalisation of GYIMSTC Ltd to be at least HK$1,500,000,000 (~A$260 million), as required under the Hong Kong Stock Exchange Listing Rules for biotech companies (Chapter 18A provisions). G Medical will also provide a submission to the ASX to determine the requirements to proceed with the proposed IPO of GYIMSTC Ltd. G Medical advises that it previously disclosed this potential IPO in its ASX announcement dated 22 May 2017 in respect of the joint venture agreement in China. G Medical CEO Dr. Yacov Geva said, “Our proposed listing of GYIMSTC Ltd on the Stock Exchange of Hong Kong Limited is an important step in our global growth ambitions, shows our continued investment in the Chinese market and delivers an important avenue through which to raise the capital required to continue to innovate and introduce world-leading mobile health monitoring solutions to global markets.” The Company has included its corporate structure below to exhibit where the proposed entity to be listed on the Hong Kong Stock Exchange, Guangzhou Yimei Innovative Medical Science and Technology Co. Ltd, lies within the corporate structure. Corporate Advisors Otsana Capital 108 Outram Street West Perth WA 6005 Telephone: +61 8 9486 7244 www.otsana.com Investor Relations Viriathus Australia Level 8/525 Flinders Street Melbourne VIC 3000 Telephone: +61 2 8667 5360 www.viriathus.com Media Enquiries Closer Communications David Wolf Telephone: + 61 411 111 787 david@closer.com.au About G Medical Innovations G Medical (ASX: GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity. The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories. For more information on G Medical, please visit www.gmedinnovations.com